Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
Yes, but the problem is that these are not meant to be forever drugs. You’re supposed to take them in conjunction with changing diet and exercise habits so that you can go off the drug and maintain a healthy weight on your own. Often people get off of these drugs without having done the work, and they end up right back where they started.